Journal of Ophthalmic Science

Submit Manuscript

Journal of Ophthalmic Science· ISSN 2470-0436· Open Access Pub

Current Issue

Volume 3, Issue 3 — published 12 January 2026 to 3 July 2026.

  • 3Volume
  • 3Issue
  • 2Articles
  • 1-22Pages
  • CC BY 4.0Open access

Archive Aims & scope

I

About this issue

Volume 3, Issue 3 contains 2 articles, listed below in page order. This is the complete issue: every article assigned to it appears here, and nothing from the archive is shown alongside them.

Publication
Each article is published on its own date and takes its page range as it appears.
Status
Volume 3, Issue 3 is the most recent issue containing published articles. Every article in it is final and citable: each carries a registered DOI, a page range and a publication date.
Access and reuse
Every article is open access under CC BY 4.0. Authors retain copyright and may self-archive without embargo. There is no subscription, paywall or registration.
Identifiers
ISSN 2470-0436 (online). Every article carries a Crossref DOI under the prefix 10.14302, resolving to the article's own page.

II

Contents

Each entry gives the record as published: the authors in submission order, the dates the manuscript was received, accepted and published, its page range, its DOI, and the full text in three formats.

Article 01 12 January 2026

Case Report

Conjunctival Resection for Mooren's Ulcer Refractory to Medical Therapy: A Case Report

Mahmood Al-Noufali, Shihab Al-Habsi, Mohamed Imtiaz, Nabila Al-Julandani, Mohammed Al-Yarabi

Corresponding author: Mohammed Al-Yarabi

Field
Cornea and ocular surface
Subject
Mooren's ulcer — peripheral ulcerative keratitis
Assessment
Rheumatological, immunological and microbiological workup; HLA genotyping; histopathology of the excised conjunctiva
Intervention
Conjunctival resection after medical therapy failed to control the disease
Follow-up
Six months after resection
Abstract

Purpose

To report a rare case of Mooren’s ulcer in a healthy young male without systemic autoimmune disease, and to highlight the effectiveness of conjunctival resection as therapy for cases unresponsive to medical management.

Case report

A 34-year-old immunocompetent male presented with progressive peripheral corneal ulceration in the left eye. Extensive systemic and infectious evaluations, including rheumatologic, immunologic, and microbiological testing, were unremarkable. Human leukocyte antigen genotyping was DR17(03)-negative and DQ2-positive. Rheumatological evaluation yielded no definitive systemic diagnosis. Despite immunosuppressive therapy with adjuvant medications, the epithelial defect and stromal inflammation persisted. The patient underwent conjunctival resection, resulting in marked reduction in inflammation, rapid re-epithelialization, and structural stabilization of the cornea. Histopathology of excised conjunctiva showed nonspecific inflammation without granulomatous changes, vasculitis, or neoplastic features. During follow-up, patient remained in remission with visual acuity preserved at 6/6 bilaterally and no recurrence.

Conclusion

Mooren’s ulcer is rare but vision-threatening. Early recognition, comprehensive evaluation, and timely surgical intervention can be vision-saving. This case highlights the role of a multidisciplinary approach and supports conjunctival resection as a useful adjunct in refractory disease. Long-term follow-up is essential.

DOI
10.14302/issn.2470-0436.jos-25-5905
Citation
Journal of Ophthalmic Science 3(3), 1-13
Pages
pp. 1-13
Dates
Received 11 December 2025 · Accepted 29 December 2025 · Published 12 January 2026
License
CC BY 4.0 · authors retain copyright

KeywordsMooren’s Ulcer · Peripheral ulcerative keratitis · Conjunctival resection · Idiopathic · Corneal ulcer · Ocular inflammation

Full text PDF XML Cite

Article 02 3 July 2026

Case Report

Herpes Zoster Ophthalmicus Presenting with Suspected Orbital Myositis Following Recent Recombinant Zoster Vaccination

The authors describe a temporal association with recent recombinant zoster vaccination. A single case report cannot establish causation.

Muhammad Awan, Musa Azhar, Mujtaba Khan, Ali Qureshi, Fawaz Qazi, Dawood Hafeez, Jeffrey Sheridan

Corresponding author: Muhammad Awan

  • Alabama College of Osteopathic Medicine, Dothan, Alabama
  • University of Central Florida, Orlando, Florida
  • Orlando Health Hospital, Clermont, Florida
Field
Orbit, oculoplastic and lacrimal
Subject
Herpes zoster ophthalmicus with suspected orbital myositis
Assessment
CT and MRI of the brain, and varicella-zoster virus polymerase chain reaction. Orbital imaging was deferred, so the myositis remained a clinical impression — which is why the title says suspected
Intervention
Intravenous aciclovir, then oral valaciclovir
Follow-up
To discharge on day three; the diplopia had not resolved
Abstract

Herpes zoster ophthalmicus (HZO) is a manifestation of varicella-zoster virus (VZV) reactivation involving the ophthalmic division of the trigeminal nerve, carrying significant risk of vision-threatening complications. Diplopia in HZO is often attributed to cranial nerve palsy, although orbital myositis remains a rare and underrecognized cause. We present a 79-year-old male who developed right-sided headache, binocular diplopia, and a V1 vesicular rash two weeks after receiving the recombinant zoster vaccine. Examination revealed restriction of extraocular movements without a localizing cranial nerve pattern, raising suspicion for orbital myositis. Neuroimaging was unremarkable, and VZV polymerase chain reaction confirmed the diagnosis of HZO. The patient received antiviral therapy and was discharged in stable condition after three days. This case highlights HZO presenting with suspected orbital myositis in temporal association with vaccination and underscores the need for vigilance for uncommon neuro-ophthalmic manifestations, as early recognition and treatment are essential to prevent vision-threatening complications. Given the patient's advanced age, this case also emphasizes the possibility that age-related immunosenescence may contribute to VZV reactivation and the development of HZO-related ocular complications. Potential therapeutic approaches targeting age-related immune dysfunction are also considered.

DOI
10.14302/issn.2470-0436.jos-26-6357
Citation
Journal of Ophthalmic Science 3(3), 14-22
Pages
pp. 14-22
Dates
Received 31 May 2026 · Accepted 23 June 2026 · Published 3 July 2026
License
CC BY 4.0 · authors retain copyright

KeywordsHerpes zoster ophthalmicus · orbital myositis · varicella-zoster virus · diplopia · recombinant zoster vaccine

Full text PDF XML Cite

III

What was applied to these articles

These concise publication requirements link to the journal’s full editorial policies and author instructions.

Peer review
Manuscripts that proceed to external peer review are normally evaluated under the single-blind model by at least two independent ophthalmology specialists.
Case reports
Both articles in this issue are case reports. The journal asks case reports to follow the CARE checklist and to carry patient consent.
Patient consent and privacy
Clinical photographs showing periocular or facial features require explicit patient consent for publication. Fundus photographs and imaging without patient identifiers require clinical consent but not publication consent.
Ethics
Research involving human participants requires documented institutional review board approval and compliance with the Declaration of Helsinki. Interventional clinical trials must be registered in an accepted public registry at or before the first participant provides consent for enrollment.
Corrections and retractions
Minor post-publication errors are corrected by erratum or corrigendum; errors affecting the conclusions by a correction notice with an updated version; evidence of misconduct by retraction under COPE guidance. No article in this issue carries any such notice.
Charges and independence
The article processing charge is USD 1,200, or USD 900 for students, billed only after acceptance. There is no submission fee. Editorial decisions rest on scientific merit and are independent of article charges, membership and any optional service.

Editorial policies Instructions for authors

Submit to the Journal of Ophthalmic Science

Clinical and translational ophthalmology, reviewed by ophthalmology specialists and published open access under CC BY 4.0.

Submit a manuscript Read the author instructions

Journal of Ophthalmic Science · ISSN 2470-0436 (online) · published by Open Access Pub · DOI prefix 10.14302.

Menu